GSK PLC Sponsored ADR (GSK) – What Are Analysts Thinking About This Stock?

GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nineteen analysts that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $56.30.

A number of analysts have recently commented on GSK shares. HSBC reissued a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Deutsche Bank reaffirmed a “neutral” rating on shares of GSK in a research note on Tuesday, September 29th. Wolfe Research began coverage on GSK in a report on Friday, October 9th. They set an “outperform” rating and a $70.00 price objective on the stock. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of GSK in a report on Sunday, August 2nd.

Get Our Latest Stock Analysis on GSK

Institutional Investors Weigh In On GSK

A number of hedge funds have recently added to or reduced their stakes in the stock. Mondrian Investment Partners LTD raised its position in shares of GSK by 1.1% in the 3rd quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company’s stock valued at $239,210,000 after acquiring an additional 55,116 shares during the period. Equity Investment Corp raised its holdings in shares of GSK by 8.9% in the third quarter. Equity Investment Corp now owns 3,560,824 shares of the pharmaceutical company’s stock valued at $171,525,000 after purchasing an additional 291,059 shares during the last quarter. Russell Investments Group Ltd. lifted its position in GSK by 2.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,060,376 shares of the pharmaceutical company’s stock worth $51,078,000 after buying an additional 22,275 shares in the last quarter. NewEdge Advisors LLC boosted its position in GSK by 842.9% during the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after purchasing an additional 852,437 shares during the last quarter. Finally, First Trust Advisors LP grew its position in shares of GSK by 10.5% in the 3rd quarter. First Trust Advisors LP now owns 708,091 shares of the pharmaceutical company’s stock valued at $34,109,000 after acquiring an additional 67,456 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Stock Down 1.3%

Shares of NYSE:GSK opened at $48.60 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.56 and a debt-to-equity ratio of 1.18. The company has a fifty day simple moving average of $49.32 and a 200 day simple moving average of $52.38. The firm has a market cap of $98.31 billion, a PE ratio of 10.37, a price-to-earnings-growth ratio of 2.21 and a beta of 0.29. GSK has a 12-month low of $45.81 and a 12-month high of $61.69.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be issued a dividend of $0.4518 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $1.81 annualized dividend and a yield of 3.7%. This is an increase from GSK’s previous quarterly dividend of $0.4515. GSK’s payout ratio is 61.81%.

About GSK

(Get Free Report)

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

Featured Articles

Analyst Recommendations for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.